REAL 3: A randomised, multinational, active-controlled, (open-labelled), dose finding, (double blinded), parallel group trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin FlexPro) in growth hormone treatment naive pre-pubertal children with growth hormone deficiency (NCT02616562)